The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

The stock's rise snapped a four-day losing streak.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

2025 Healthcare & Pharmaceuticalscategory US FDA issues labeling changes for testosterone products February 28, 2025 Healthcare & Pharmaceuticalscategory India's Sun Pharma aims to launch its ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...